Oppenheimer Reiterates Rating, Raises Price Target On Physicians Realty Trust On Acquisition Update And Equity Offering


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


In a report published Friday, Oppenheimer analyst Steve Manaker reiterated an Outperform rating on

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Physicians Realty Trust (NYSE: DOC), and raised the price target from $16.75 to $18.00.In the report, Oppenheimer noted, “We maintain our Outperform rating and raise our price target to $18 despite lowering our 2015 FFO estimate. Our new price target implies a 13.8% total return, including the 5.8% dividend yield. DOC closed $105 million of acquisitions in 4Q14 and is starting 2015 with $206 million of acquisitions near closing. In order to finance the pipeline, DOC announced the sale of 15 million shares. Previously, we assumed a similar-sized offering but at the end of 2Q15. This change is lowering our 2015 FFO estimate to $1.00 from $1.03, but our 4Q15 estimate remains the same—this is our stable quarterly run-rate FFO est. for DOC assuming $450 million of acquisitions done in the first nine months of 2015.”Physicians Realty Trust closed on Thursday at $16.64.
Posted In: Analyst ColorPrice TargetAnalyst RatingsOppenheimerSteve Manaker